Compare IAC/Interactivecorp (PPLI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Summit Therapeutics Inc — how do they compare? IAC/Interactivecorp trades at $40.99 (market cap $3.05B), while Summit Therapeutics Inc trades at $17.4 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 4.5× IAC/Interactivecorp's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and Summit Therapeutics Inc for 16 Days on average.
| PPLI | SMMT | |
|---|---|---|
Market Cap | $3.05B | $13.71B |
Volume | 931,019 | 6,173,057 |
Sector | Media | Health |
52-Week High | $47.62 | $26.38 |
52-Week Low | $31.52 | $12.43 |
Typical Hold Time | 79 Days | 16 Days |
Enterprise Value | $3.53B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.85, up 0.64% on the day, with a bullish technical signal from moving averages. The stock has shown volatile earnings, missing estimates in Q4 2025 and Q1 2026 but beating in Q2 2026. Recent news highlights potential M&A activity, with MGM Resorts considering a bid for the company after PPLI withdrew its own offer to buy MGM, driving significant price movement. Valuation ratios appear attractive with a P/E of 6.92 and P/B of 0.6, though profitability metrics are mixed amid revenue declines from $5.2B in 2022 to $2.4B in 2025.
The outlook is cautiously optimistic due to strong analyst support (71.43% buy ratings) and speculative M&A upside, but risks include inconsistent earnings, high debt levels, and competitive pressures in the media sector. Net cash flow turned deeply negative in 2025 at -$820.42M, underscoring financial volatility. Investors should weigh the low valuation against execution challenges and industry headwinds.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
